Grepafloxacin vs Cefixime for Gonorrhea in Women
Author Information
Author(s): T.F. Mroczkowski, E.W. Hook III, R.B. Jones, W.M. McCormack, D.H. Martins
Primary Institution: Tulane University School of Medicine
Hypothesis
To compare the efficacy and tolerance of single-dose grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in women.
Conclusion
Single-dose grepafloxacin is at least as effective as cefixime for treating women with uncomplicated cervical gonorrhea.
Supporting Evidence
- 99% of cervical infections were eradicated in both treatment groups.
- Grepafloxacin cured all extragenital infections, while cefixime failed to cure some.
- Both drugs were well tolerated, with mild to moderate adverse events.
- 31% of pharyngeal infections failed to respond to cefixime.
Takeaway
This study tested two medicines to see which one works better for treating a common infection in women. Both worked well, but grepafloxacin was especially good at curing infections in the throat and rectum.
Methodology
Women with suspected uncomplicated gonorrhea were randomized to receive single oral doses of grepafloxacin or cefixime, and efficacy was evaluated through follow-up assessments.
Potential Biases
The study was open-label, which may introduce bias in reporting outcomes.
Limitations
Some patients were lost to follow-up, and the study did not primarily focus on C. trachomatis infections.
Participant Demographics
380 women aged 15 to 55 years, predominantly black (87%), with some Caucasian and other racial origins.
Statistical Information
P-Value
0.043
Confidence Interval
95% CI, -9.75, 4.1%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website